Tenaya Therapeutics, Inc.
General ticker "TNYA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $130.9M (TTM average)
Tenaya Therapeutics, Inc. follows the US Stock Market performance with the rate: 38.6%.
Estimated limits based on current volatility of 8.3%: low 0.58$, high 0.68$
Factors to consider:
- Earnings expected soon, date: 2026-03-09 bmo
- Total employees count: 97 (-30.7%) as of 2024
- Top business risk factors: Operational and conduct risks, High risk of business failure, Early stage company risks, Development risks, Product development delays
- Current price 27.8% below estimated low
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.08$, 3.40$]
- 2025-12-31 to 2026-12-31 estimated range: [1.13$, 3.41$]
Financial Metrics affecting the TNYA estimates:
- Positive: with PPE of -1.1 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -71.32 <= 0.01
- Positive: Investing cash flow per share per price, % of 0.89 > -0.63
- Positive: Shareholder equity ratio, % of 77.42 > 64.29
- Positive: Inventory ratio change, % of 0 <= 0
Short-term TNYA quotes
Long-term TNYA plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $125.62MM | $131.19MM | $115.95MM |
| Operating Income | $-125.62MM | $-131.19MM | $-115.95MM |
| Non-Operating Income | $1.96MM | $7.11MM | $4.82MM |
| R&D Expense | $94.54MM | $98.04MM | $86.74MM |
| Income(Loss) | $-123.67MM | $-124.08MM | $-111.13MM |
| Profit(Loss)* | $-123.67MM | $-124.08MM | $-111.13MM |
| Stockholders Equity | $243.38MM | $139.42MM | $92.85MM |
| Assets | $278.94MM | $170.51MM | $119.94MM |
| Operating Cash Flow | $-104.42MM | $-102.07MM | $-90.50MM |
| Capital expenditure | $20.63MM | $1.24MM | $1.02MM |
| Investing Cash Flow | $83.65MM | $48.72MM | $1.13MM |
| Financing Cash Flow | $77.77MM | $4.05MM | $47.75MM |
| Earnings Per Share** | $-2.76 | $-1.68 | $-1.31 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.